Subtopic Deep Dive
Follicular Lymphoma Genetic Pathogenesis
Research Guide
What is Follicular Lymphoma Genetic Pathogenesis?
Follicular lymphoma genetic pathogenesis refers to the molecular mechanisms driven by t(14;18) BCL2 translocation and secondary mutations in epigenetic regulators that initiate and promote this indolent B-cell lymphoma.
The t(14;18)(q32;q21) translocation constitutively overexpresses BCL2, blocking apoptosis in germinal center B cells (Kridel et al., 2012). Whole-genome sequencing reveals frequent mutations in histone-modifying genes like EZH2, CREBBP, and EP300 in over 70% of cases (Morin et al., 2011, 1592 citations). Clonal evolution from early progenitors with suppressed antigen presentation drives progression to aggressive disease (Green et al., 2015).
Why It Matters
Genetic drivers like t(14;18) and EZH2 mutations enable targeted therapies such as BCL2 inhibitors (venetoclax) in clinical trials for relapsed follicular lymphoma. Kridel et al. (2012) detail how secondary genetic hits predict transformation risk, guiding risk-stratified treatment in indolent yet incurable cases comprising 20-30% of adult lymphomas. Morin et al. (2011) identified epigenetic mutations shared with DLBCL, informing combination therapies; WHO classifications by Alaggio et al. (2022, 3291 citations) and Campo et al. (2011, 1957 citations) standardize diagnosis for precision medicine.
Key Research Challenges
Clonal Heterogeneity Mapping
Tumors exhibit intraclonal diversity from early progenitors, complicating targeted therapy (Green et al., 2015). Whole-genome sequencing shows branching evolution, requiring single-cell approaches to track transformation. Current bulk sequencing misses rare subclones driving relapse (Kridel et al., 2012).
Epigenetic Mutation Functional Impact
Mutations in CREBBP, EP300, and EZH2 alter histone acetylation/methylation, but downstream effects on gene expression remain unclear (Morin et al., 2011). Validating causality in vivo is challenging due to lymphoma's indolent nature. Therapeutic reversibility of these hits lacks clinical validation.
Transformation Predictor Identification
Predicting indolent-to-aggressive shift relies on secondary hits, but no reliable biomarkers exist (Kridel et al., 2012). Integrating multi-omics data struggles with small cohorts. WHO updates highlight need for genomic risk models (Alaggio et al., 2022).
Essential Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos et al. · 2022 · Leukemia · 3.3K citations
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elı́as Campo, Steven H. Swerdlow, Nancy L. Harris et al. · 2011 · Blood · 2.0K citations
Abstract The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of dist...
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin, María Méndez-Lago, Andrew J. Mungall et al. · 2011 · Nature · 1.6K citations
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgkin lymphomas (NHLs). Here we sequenced tumour and matched normal DNA from 13 DLBCL cases and one ...
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Felipe Suárez · 2006 · Blood · 440 citations
Non-Hodgkin lymphomas develop from nodal and extranodal lymphoid tissues. A distinct subset of extranodal lymphomas arising from B cells of the marginal zone (MZ) of mucosa-associated lymphoid tiss...
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
Elaine S. Jaffe, Nancy L. Harris, Harald Stein et al. · 2008 · Blood · 374 citations
Abstract In the past 50 years, we have witnessed explosive growth in the understanding of normal and neoplastic lymphoid cells. B-cell, T-cell, and natural killer (NK)–cell neoplasms in many respec...
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek, Othman Al‐Sawaf · 2021 · American Journal of Hematology · 357 citations
Abstract Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukem...
Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation
Michael R. Green, Shingo Kihira, Chih Long Liu et al. · 2015 · Proceedings of the National Academy of Sciences · 349 citations
Significance Follicular lymphoma (FL) is a disease characterized by multiple relapses that are linked by a common progenitor bearing only a subset of the mutations found within the tumor that prese...
Reading Guide
Foundational Papers
Start with Kridel et al. (2012) for t(14;18)/secondary hits overview; Morin et al. (2011) for epigenetic mutations discovery; Campo et al. (2011, 1957 citations) for WHO context.
Recent Advances
Alaggio et al. (2022, 3291 citations) for 5th WHO edition; Green et al. (2015) on progenitor mutations.
Core Methods
Whole-genome sequencing for mutations (Morin 2011); Ig gene sequencing for origins; WHO multidisciplinary classification (Alaggio 2022).
How PapersFlow Helps You Research Follicular Lymphoma Genetic Pathogenesis
Discover & Search
Research Agent uses searchPapers with 'follicular lymphoma t(14;18) epigenetic mutations' to retrieve Morin et al. (2011); citationGraph maps 1592 citing papers on histone modifiers; findSimilarPapers expands to Green et al. (2015); exaSearch queries 'BCL2 clonal evolution WGS' for 250M+ OpenAlex hits.
Analyze & Verify
Analysis Agent applies readPaperContent on Kridel et al. (2012) to extract t(14;18) mechanisms; verifyResponse with CoVe cross-checks mutation frequencies against Morin et al. (2011); runPythonAnalysis on supplementary mutation data uses pandas for clonal fraction stats and matplotlib for evolution plots; GRADE grades evidence as high for epigenetic drivers.
Synthesize & Write
Synthesis Agent detects gaps in transformation predictors from Kridel/Green papers, flags contradictions in mutation prevalence; Writing Agent uses latexEditText for manuscript sections, latexSyncCitations for 10+ refs, latexCompile for figures, exportMermaid for clonal evolution diagrams.
Use Cases
"Analyze clonal evolution in FL from WGS data in recent papers"
Research Agent → searchPapers('follicular lymphoma WGS clonal evolution') → Analysis Agent → runPythonAnalysis(pandas on mutation tables from Green 2015 supp) → matplotlib plot of subclonal fractions.
"Draft LaTeX review on FL epigenetic mutations with citations"
Synthesis Agent → gap detection(Morin 2011 + Kridel 2012) → Writing Agent → latexEditText('epigenetic drivers section') → latexSyncCitations(Alaggio 2022 et al.) → latexCompile(PDF review).
"Find code for FL mutation analysis from papers"
Research Agent → paperExtractUrls(Kridel 2012) → Code Discovery → paperFindGithubRepo → githubRepoInspect(mutation caller scripts) → runPythonAnalysis(local sandbox).
Automated Workflows
Deep Research workflow scans 50+ FL papers via searchPapers → citationGraph → structured report on t(14;18) evolution (Kridel 2012 cited 305x). DeepScan's 7-steps verify epigenetic mutation impacts: readPaperContent(Morin 2011) → CoVe → runPythonAnalysis. Theorizer generates hypotheses on EZH2/BCL2 interactions from Green et al. (2015) progenitors.
Frequently Asked Questions
What defines FL genetic pathogenesis?
Hallmark t(14;18) BCL2 translocation plus mutations in EZH2 (44%), CREBBP (32%), EP300 (21%) (Morin et al., 2011; Kridel et al., 2012).
What sequencing methods identify FL mutations?
Whole-genome/exome sequencing of tumor-normal pairs reveals recurrent hits; one FL case in Morin et al. (2011) study. Single-cell sequencing tracks progenitors (Green et al., 2015).
What are key papers?
Morin et al. (2011, Nature, 1592 citations) on histone mutations; Kridel et al. (2012) on pathogenesis; Alaggio et al. (2022, Leukemia, 3291 citations) WHO classification.
What open problems exist?
Predicting transformation from indolent FL; functional validation of epigenetic drivers; multi-omics integration for therapy response (Kridel et al., 2012; Green et al., 2015).
Research Lymphoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Follicular Lymphoma Genetic Pathogenesis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lymphoma Diagnosis and Treatment Research Guide